MX2009004147A - Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. - Google Patents
Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.Info
- Publication number
- MX2009004147A MX2009004147A MX2009004147A MX2009004147A MX2009004147A MX 2009004147 A MX2009004147 A MX 2009004147A MX 2009004147 A MX2009004147 A MX 2009004147A MX 2009004147 A MX2009004147 A MX 2009004147A MX 2009004147 A MX2009004147 A MX 2009004147A
- Authority
- MX
- Mexico
- Prior art keywords
- peptides
- canceres
- present
- peptide vaccines
- depdc1
- Prior art date
Links
- 101000950642 Homo sapiens DEP domain-containing protein 1A Proteins 0.000 title abstract 2
- 101001027631 Homo sapiens Kinesin-like protein KIF20B Proteins 0.000 title abstract 2
- 102100037691 Kinesin-like protein KIF20B Human genes 0.000 title abstract 2
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102100037753 DEP domain-containing protein 1A Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85257506P | 2006-10-17 | 2006-10-17 | |
| PCT/JP2007/001122 WO2008047473A1 (en) | 2006-10-17 | 2007-10-16 | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004147A true MX2009004147A (es) | 2009-06-15 |
Family
ID=39313729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004147A MX2009004147A (es) | 2006-10-17 | 2007-10-16 | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8557955B2 (https=) |
| EP (7) | EP2476698B1 (https=) |
| JP (2) | JP5339292B2 (https=) |
| KR (4) | KR101493773B1 (https=) |
| CN (5) | CN102850435B (https=) |
| AU (1) | AU2007311395B2 (https=) |
| BR (1) | BRPI0717651A2 (https=) |
| CA (2) | CA2915560A1 (https=) |
| DK (1) | DK2091965T3 (https=) |
| ES (4) | ES2545817T3 (https=) |
| IL (4) | IL198186A (https=) |
| MX (1) | MX2009004147A (https=) |
| PL (1) | PL2091965T3 (https=) |
| PT (1) | PT2091965E (https=) |
| RU (1) | RU2469044C2 (https=) |
| SG (2) | SG10201502098YA (https=) |
| WO (1) | WO2008047473A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1856278A2 (en) | 2005-02-10 | 2007-11-21 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| ES2632123T3 (es) * | 2007-08-20 | 2017-09-11 | Oncotherapy Science, Inc. | Péptido CDH3 y agente medicinal que comprende el mismo |
| JP5640263B2 (ja) * | 2008-08-28 | 2014-12-17 | オンコセラピー・サイエンス株式会社 | Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法 |
| CN102439147A (zh) * | 2009-03-04 | 2012-05-02 | 肿瘤疗法科学股份有限公司 | Vangl1肽及包含它们的疫苗 |
| TW201211250A (en) * | 2010-09-07 | 2012-03-16 | Oncotherapy Science Inc | VANGL1 peptides and vaccines including the same |
| ES2647900T3 (es) * | 2011-08-12 | 2017-12-27 | Oncotherapy Science, Inc. | Péptidos MPHOSPH1 y vacunas que incluyen los mismos |
| JP2013058294A (ja) * | 2011-09-09 | 2013-03-28 | Toshiba Corp | 磁気記録媒体及び磁気記録媒体の製造方法 |
| RU2746407C1 (ru) | 2012-02-23 | 2021-04-13 | Стейдж Селл Терапеутикс Гмбх | Хроматографическое выделение клеток и других сложных биологических материалов |
| SG11201405578TA (en) * | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
| JP6041297B2 (ja) * | 2012-08-24 | 2016-12-07 | 国立大学法人山口大学 | 犬リンパ腫の診断方法及び診断キット |
| US20160060652A1 (en) * | 2013-03-13 | 2016-03-03 | Lapian's Corp | Microvesicle and method for producing the same |
| BR112016024072B1 (pt) | 2014-04-16 | 2021-02-09 | Juno Therapeutics Gmbh | método in vitro de estimular uma população de células |
| RU2684911C2 (ru) * | 2014-10-07 | 2019-04-16 | Ситлимик Инк. | Пептид, полученный из hsp70, фармацевтическая композиция для лечения или профилактики рака, содержащая такой пептид, индуктор иммунного ответа и способ получения антиген-презентирующей клетки |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| CN107428815B (zh) | 2015-03-09 | 2021-07-09 | Cytlimic公司 | 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法 |
| AU2016244570B2 (en) | 2015-04-07 | 2020-08-27 | Nec Corporation | Medicine |
| TWI769984B (zh) * | 2015-08-12 | 2022-07-11 | 日商腫瘤療法 科學股份有限公司 | 來自ｄｅｐｄｃ１之胜肽及含此之疫苗 |
| EP3360885A4 (en) | 2015-10-08 | 2019-04-24 | Oncotherapy Science, Inc. | PEPTIDE DERIVED FROM MPHOSPH1 AND VACCINE WITH IT |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| JP7194020B2 (ja) | 2015-10-22 | 2022-12-21 | ジュノ セラピューティクス ゲーエムベーハー | 細胞の培養方法ならびにそのためのキットおよび装置 |
| AU2017342189B2 (en) | 2016-10-11 | 2023-09-21 | Nec Corporation | Medicine |
| TW201831503A (zh) * | 2016-11-18 | 2018-09-01 | 日商腫瘤療法 科學股份有限公司 | 對於ｔｈ１細胞的ｍｐｈｏｓｐｈ１抗原決定位胜肽及包含其之疫苗 |
| TW201831502A (zh) * | 2016-11-18 | 2018-09-01 | 日商腫瘤療法 科學股份有限公司 | 對於ｔｈ１細胞的ｄｅｐｄｃ１抗原決定位胜肽及包含其之疫苗 |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| EP4649954A3 (en) | 2017-01-25 | 2025-12-17 | Ose Immunotherapeutics | Method for manufacturing a stable emulsion for peptide delivery |
| JP7339160B2 (ja) | 2017-04-27 | 2023-09-05 | ジュノ セラピューティクス ゲーエムベーハー | オリゴマー粒子試薬およびその使用方法 |
| HUE061840T2 (hu) * | 2017-07-12 | 2023-08-28 | Nouscom Ag | Egy univerzális vakcina, amely közös tumor neoantigéneken alapul a mikroszatellita-instabilitás (MSI) rákos megbetegedések megelõzésére és kezelésére |
| US11338028B2 (en) * | 2017-12-13 | 2022-05-24 | Inovio Pharmaceuticals, Inc. | Cancer vaccines targeting LEMD1 and uses thereof |
| CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| EP3874024A1 (en) | 2018-10-31 | 2021-09-08 | Juno Therapeutics GmbH | Methods for selection and stimulation of cells and apparatus for same |
| CN112142824B (zh) * | 2019-06-27 | 2022-03-11 | 深圳市东贵博康生化科技有限公司 | 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用 |
| WO2021060343A1 (ja) * | 2019-09-24 | 2021-04-01 | オンコセラピー・サイエンス株式会社 | Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体 |
| ES3001611T3 (en) * | 2020-10-15 | 2025-03-05 | Myneo Nv | Method, system and computer program product for determining peptide immunogenicity |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| RU94038427A (ru) | 1991-08-26 | 1996-10-20 | Сайтел Корпорейшн (US) | Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации |
| HUT68510A (en) | 1991-08-26 | 1995-06-28 | Cytel Corp | Process for producing hla-restricted hapatitis b virus ctl epitopes and pharmaceutical compositions containing them |
| WO1994020141A1 (en) * | 1993-03-11 | 1994-09-15 | The University Of Southern California | Therapeutic strategies for immunoinfective cluster virus infections |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| US20030198642A1 (en) | 1995-08-03 | 2003-10-23 | Johannes J. Geuze | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| EP0960204A4 (en) | 1996-07-26 | 2002-01-23 | Sloan Kettering Inst Cancer | METHODS AND REAGENTS FOR GENETIC IMMUNIZATION |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US7001999B1 (en) | 1998-04-15 | 2006-02-21 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| ATE399179T1 (de) * | 1998-09-30 | 2008-07-15 | Corixa Corp | Zusammensetzungen und verfahren für wt1- spezifische immunotherapie |
| US20040241726A1 (en) | 1999-01-06 | 2004-12-02 | Chondrogene Limited | Method for the detection of allergies related gene transcripts in blood |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| US6291663B1 (en) | 1999-03-03 | 2001-09-18 | Board Of Trustees Of The University Of Arkansas | TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma |
| US7030215B2 (en) * | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| EP1259812A2 (en) * | 1999-05-28 | 2002-11-27 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| CA2420543C (en) | 2000-08-22 | 2013-04-02 | Agensys, Inc. | Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers |
| EP1325120A4 (en) | 2000-10-12 | 2005-05-25 | Nuvelo Inc | NUCLEIC ACIDS AND POLYPEPTIDES |
| EP1911461B1 (en) | 2000-10-19 | 2011-12-07 | Epimmune Inc. | HLA class I and II binding peptides and their uses |
| WO2002046416A2 (en) | 2000-12-04 | 2002-06-13 | Argonex Pharmaceuticals | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2003207795B2 (en) * | 2002-01-31 | 2009-01-08 | Wyeth | Aggrecanase molecules |
| WO2003083074A2 (en) | 2002-03-28 | 2003-10-09 | Idec Pharmaceuticals Corporation | Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| WO2005007090A2 (en) | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| US7915036B2 (en) | 2004-09-13 | 2011-03-29 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions comprising T cell receptors and methods of use thereof |
| EP1856278A2 (en) | 2005-02-10 | 2007-11-21 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| JP2006302684A (ja) | 2005-04-21 | 2006-11-02 | D D K Ltd | カードコネクタ |
| CN101283106A (zh) | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | 小细胞肺癌的诊断方法 |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| TWM336439U (en) * | 2008-02-14 | 2008-07-11 | Optivision Technology Inc | Diffuser capable of light condensing |
| JP5640263B2 (ja) | 2008-08-28 | 2014-12-17 | オンコセラピー・サイエンス株式会社 | Ｄｅｐｄｃ１ポリペプチドを使用した膀胱癌の治療または予防のための方法 |
| ES2647900T3 (es) | 2011-08-12 | 2017-12-27 | Oncotherapy Science, Inc. | Péptidos MPHOSPH1 y vacunas que incluyen los mismos |
-
2007
- 2007-10-16 DK DK07827901.5T patent/DK2091965T3/da active
- 2007-10-16 EP EP12155446.3A patent/EP2476698B1/en active Active
- 2007-10-16 EP EP12155448.9A patent/EP2476699B1/en active Active
- 2007-10-16 CN CN201210305732.2A patent/CN102850435B/zh active Active
- 2007-10-16 US US12/445,729 patent/US8557955B2/en active Active
- 2007-10-16 KR KR1020147011020A patent/KR101493773B1/ko active Active
- 2007-10-16 ES ES12155444.8T patent/ES2545817T3/es active Active
- 2007-10-16 KR KR1020157000123A patent/KR101527473B1/ko active Active
- 2007-10-16 EP EP12155444.8A patent/EP2476697B1/en active Active
- 2007-10-16 JP JP2009516776A patent/JP5339292B2/ja active Active
- 2007-10-16 CN CN2007800467286A patent/CN101568550B/zh active Active
- 2007-10-16 ES ES07827901T patent/ES2415958T3/es active Active
- 2007-10-16 KR KR1020147022451A patent/KR101543622B1/ko active Active
- 2007-10-16 CN CN201210305207.0A patent/CN102850433B/zh active Active
- 2007-10-16 PT PT78279015T patent/PT2091965E/pt unknown
- 2007-10-16 EP EP20130189408 patent/EP2687541A1/en not_active Withdrawn
- 2007-10-16 CN CN201610069574.3A patent/CN105693843A/zh active Pending
- 2007-10-16 MX MX2009004147A patent/MX2009004147A/es active IP Right Grant
- 2007-10-16 EP EP20130189400 patent/EP2695895A1/en not_active Withdrawn
- 2007-10-16 BR BRPI0717651-1A2A patent/BRPI0717651A2/pt not_active IP Right Cessation
- 2007-10-16 AU AU2007311395A patent/AU2007311395B2/en not_active Ceased
- 2007-10-16 WO PCT/JP2007/001122 patent/WO2008047473A1/en not_active Ceased
- 2007-10-16 SG SG10201502098YA patent/SG10201502098YA/en unknown
- 2007-10-16 CA CA2915560A patent/CA2915560A1/en not_active Abandoned
- 2007-10-16 CN CN201210305211.7A patent/CN102850434B/zh active Active
- 2007-10-16 SG SG2011070455A patent/SG175566A1/en unknown
- 2007-10-16 ES ES12155446.3T patent/ES2545818T3/es active Active
- 2007-10-16 CA CA2667030A patent/CA2667030C/en not_active Expired - Fee Related
- 2007-10-16 EP EP20130189390 patent/EP2687540A1/en not_active Withdrawn
- 2007-10-16 EP EP07827901.5A patent/EP2091965B9/en active Active
- 2007-10-16 RU RU2009118432/10A patent/RU2469044C2/ru not_active IP Right Cessation
- 2007-10-16 ES ES12155448.9T patent/ES2545457T3/es active Active
- 2007-10-16 KR KR1020097010056A patent/KR101454287B1/ko active Active
- 2007-10-16 PL PL07827901T patent/PL2091965T3/pl unknown
-
2009
- 2009-04-16 IL IL198186A patent/IL198186A/en not_active IP Right Cessation
-
2011
- 2011-12-01 IL IL216713A patent/IL216713A0/en unknown
- 2011-12-01 IL IL216712A patent/IL216712A/en not_active IP Right Cessation
-
2012
- 2012-06-27 US US13/535,297 patent/US9017688B2/en active Active
- 2012-06-27 US US13/535,303 patent/US8653234B2/en active Active
- 2012-07-30 US US13/562,250 patent/US8552146B2/en active Active
- 2012-11-08 IL IL222925A patent/IL222925A0/en unknown
-
2013
- 2013-01-18 JP JP2013006870A patent/JP2013116115A/ja active Pending
-
2015
- 2015-03-24 US US14/667,560 patent/US9545437B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| MX2009009022A (es) | Vacunas de peptídicas para cánceres que expresan antígenos asociados con tumores. | |
| AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
| MX348464B (es) | Agente inductor de inmunidad. | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| MX2010005816A (es) | Epítopos de péptido de stat3. | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| GB201018125D0 (en) | Peptide | |
| BR112013002702A2 (pt) | vacina | |
| EP2370454A4 (en) | WDRPUH EPITOP PEPTIDES AND VACCINES CONTAINING THEM | |
| WO2018200814A3 (en) | Modified cyclic peptides and therapeutic use thereof | |
| MX2022003598A (es) | Composicion farmaceutica, que comprende la proteina galectina 9 recombinante estabilizada, para la prevencion o el tratamiento de la artritis reumatoide y enfermedades oseas. | |
| GB2517871A (en) | Alternaria peptides | |
| ES2529713T3 (es) | Péptidos anticonceptivos derivados de veneno de araña | |
| GB201019467D0 (en) | Therapeutic agent | |
| CY1117399T1 (el) | Συνθεσεις και μεθοδοι για προληψη και θεραπεια νευροεκφυλιστικων ασθενειων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |